Sanofi

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Sanofi's (SNY) Dupixent shows the potential to improve signs of eosinophilic esophagitis in a phase III pivotal study in children 1 to 11 years of age.

Sanofi (SNY) Dupixent Esophagitis Kids Study Meets Goal

Dupixent ® (dupilumab) P hase 3 trial shows positive results in children 1 to 11 years of age with e osinophilic e sophagitis

Press Release: Dupixent® (dupilumab) Phase 3 trial shows positive results in children 1 to 11 years of age with eosinophilic esophagitis

F itusiran prophylaxis reduced bleeds by 61% in people with hemophilia A or B, with or without inhibitors, compared to prior factor or bypassing agent prophylaxis

Press Release: Fitusiran prophylaxis reduced bleeds by 61% in people with hemophilia A or B, with or without inhibitors, compared to prior factor or bypassing agent prophylaxis

Pivotal data demonstrat e once-weekly efanesoctocog alfa provides superior bleed protection compared to prior factor prophylaxi s

Press Release: Pivotal data demonstrate once-weekly efanesoctocog alfa provides superior bleed protection compared to prior factor prophylaxis

Sanofi and Regeneron's Dupixent could be months away from regulatory approval for another skin condition in the U.S.

Is Sanofi on the Verge of Another Blockbuster?

Los Angeles, California--(Newsfile Corp. - July 7, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sanofi ("Sanofi" or "the Company") (NASDAQ: SNY) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Sanofi announced on June 30, 2022, that "the U.S. Food and Drug Administration...

ONGOING INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Sanofi with Losses of $100,000 to Contact the Firm

Los Angeles, California--(Newsfile Corp. - July 6, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sanofi ("Sanofi" or "the Company") (NASDAQ: SNY) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Sanofi announced on June 30, 2022, that "the U.S. Food and Drug Administration...

ONGOING INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Sanofi with Losses of $100,000 to Contact the Firm

AstraZeneca

Eli Lilly

Merck

Pfizer

Regeneron Pharmaceuticals

Roche Holding AG

Health care investors would be wise to keep tabs on the results of numerous drug trials scheduled to be revealed in the third quarter. Trial data can impact the stock price of a pharmaceutical company, sometimes sending it up, sometimes down.

3rd-Quarter Clinical Trial Data Could Shake Up Pharma Stocks

Los Angeles, California--(Newsfile Corp. - July 4, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sanofi ("Sanofi" or "the Company") (NASDAQ: SNY) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Sanofi announced on June 30, 2022, that "the U.S. Food and Drug Administration...

INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Sanofi with Losses of $100,000 to Contact the Firm

Sanofi Global Health launch es nonprofit Impact ® brand for 30 medicines in low-income countries

Sanofi Global Health launches nonprofit Impact® brand for 30 medicines in low-income countries

LOS ANGELES--(BUSINESS WIRE)--INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Sanofi with Losses of $100,000 to Contact the Firm

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Sanofi with Losses of $100,000 to Contact the Firm

Sanofi (SNY) pauses enrollment in late-stage studies evaluating its BTK inhibitor in multiple sclerosis and myasthenia gravis after the FDA places a partial clinical hold on these studies.

Sanofi's (SNY) Studies on BTK Inhibitor Put on Hold by FDA

Medical Properties Trust

Investors may want to consider the stocks in this article, in my view, since they meet the following value criteria:

3 Stocks With Solid Records of Sales and Earnings Growth

Arrowhead Pharmaceuticals

Global Blood Therapeutics

Novavax

Amid choppy markets, could there be potential in these top biotech stocks?

5 Top Biotech Stocks To Watch In July 2022

AbbVie

Bristol-Myers

Johnson & Johnson

Seagen

Novartis

Investors who are sweating the loss of patent protection for some of Big Pharma's top-selling drugs should relax.

Investors Need Not Be Alarmed by Drug Patent Expirations

Sanofi's (SNY) Nexviadyme is approved for the treatment of both late-onset Pompe disease and infantile-onset Pompe disease. Xenpozyme is approved for non-Central Nervous System (CNS) manifestations of acid sphingomyelinase deficiency (ASMD) disease.

Sanofi (SNY) Wins Nod for Nexviadyme & Xenpozyme in Europe

Xenpozyme ® ( olipudase alfa) approved by European Commission as first and only treatment for ASMD

Press Release: Xenpozyme® (olipudase alfa) approved by European Commission as first and only treatment for ASMD

Nexviadyme ® ( avalglucosidase alfa) approved by European Commission as a potential new standard of care for the treatment of Pompe Disease

Press Release: Nexviadyme® (avalglucosidase alfa) approved by European Commission as a potential new standard of care for the treatment of Pompe Disease

Mega-blockbuster Dupixent was just given the FDA's green light to treat patients with a chronic, progressive inflammatory disease.

Sanofi's Top-Selling Drug Just Snagged Another Approval From the FDA

There is a promising outlook for its next generation of vaccines.

Why Sanofi May Be a Frontrunner in Endemic COVID-19

GlaxoSmithKline

Sanofi and GSK's joint Covid-19 vaccine has finally produced data that could challenge the dominance of the Pfizer and Moderna vaccines.

GSK and Sanofi's Covid-19 Vaccine Could Pose a Challenge to Pfizer and Moderna

Sanofi SNY, +0.38% SAN, +3.70% and GlaxoSmithKline GSK, +1.86% said Friday that their experimental bivalent COVID-19 booster had a 72% efficacy rate against omicron, and they now plan to submit the data to regulators. The recombinant protein booster protects against the original strain of the virus as well as the beta variant, a strain of the virus that is no longer in circulation but that shares mutations with omicron that allow both variants to "escape" antibodies.

Sanofi, GSK say their next-generation COVID-19 booster has 72% efficacy against omicron

Sanofi SA (NASDAQ: SNY) and GSK plc (NYSE: GSK) have announced positive data from their vaccine trial of adjuvanted bivalent D614 and Beta (B.1.351) vaccine candidate.  "Sanofi-GSK's vaccine is the first candidate to demonstrate efficacy in a placebo-.

Sanofi-GSK's Beta-Containing COVID-19 Vaccine Shows Efficacy Against Omicron

Availability of the Q 2 202 2 Memorandum for modelling purposes

Availability of the Q2 2022 Memorandum for modelling purposes

Sanofi-GSK first to report a successful efficacy study against Omicron with COVID-19 Beta-containing vaccine

News for Sanofi Stock (SNY)